China Securities News (Intern Yang Yanying, Reporter Wang Zhoujie) - On January 12th local time, NVIDIA and the pharmaceutical company Eli Lilly announced that they would jointly invest 1 billion US dollars to establish an AI drug research laboratory in San Francisco to accelerate the drug development process.

This 1 billion US dollar investment will be used over five years for the infrastructure, computing power and talent deployment of the laboratory. Engineers from NVIDIA will collaborate with experts in biology, science and medicine from Eli Lilly to advance medical research. The related work of the laboratory will start at the beginning of this year.

Eli Lilly's CEO David Ricks said, "Combining our vast data and scientific knowledge with NVIDIA's computing capabilities and model construction expertise may completely reshape the way we know drug development."

In the medical and health field, NVIDIA has previously invested in the biotechnology company Recursion and established partnerships with industry leaders such as Novo Nordisk, Mayo Clinic, Illumina and Aeterna Zentaris. This collaboration with Eli Lilly is the latest move in NVIDIA's investment and cooperation in the AI ecosystem - some of these collaborations have attracted attention on Wall Street and have raised concerns about the "AI bubble".

NVIDIA's CEO Jensen Huang stated in the statement, "AI is changing every industry, and its most profound impact will be seen in the field of life sciences."

https://finance.eastmoney.com/a/202601133617116682.html